Back to top
more

Organogenesis (ORGO)

(Delayed Data from NSDQ)

$4.50 USD

4.50
832,000

-0.03 (-0.66%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $4.71 +0.21 (4.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Organogenesis (ORGO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of -425% and 4.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corcept Shares Rise More Than 55% in 6 Months: Here's Why

by Zacks Equity Research

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.

Zacks Equity Research

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 550% and 5.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Bioventus (BVS) Matches Q3 Earnings Estimates

by Zacks Equity Research

Bioventus (BVS) delivered earnings and revenue surprises of 0% and 4.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of -550% and 6.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 31.03% and 18.62%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

by Zacks Equity Research

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Best Momentum Stocks to Buy for January 5th

by Zacks Equity Research

ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.

Zacks Equity Research

New Strong Buy Stocks for January 5th

by Zacks Equity Research

ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.

Zacks Equity Research

Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

The Zacks Analyst Blog Highlights Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra

by Zacks Equity Research

Organogenesis, Riskified, Hooker Furniture, Stoneridge and VirTra are included in this Analyst Blog.

Sanghamitra Saha headshot

5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks

by Sanghamitra Saha

Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.

Zacks Equity Research

Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)

by Zacks Equity Research

Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Zacks Equity Research

Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?

by Zacks Equity Research

Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 3.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -86.67% and 3.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of 12.50% and 0.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Select Medical (SEM) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of -15.69% and 1.71%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Organogenesis (ORGO) Stock Jumps 5.3%: Will It Continue to Soar?

by Zacks Equity Research

Organogenesis (ORGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Organogenesis (ORGO) Q1 Earnings Lag Estimates

by Zacks Equity Research

Organogenesis (ORGO) delivered earnings and revenue surprises of -80% and 2.05%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of 3.23% and 6.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Foghorn Therapeutics Inc. (FHTX): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

Foghorn Therapeutics Inc. (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.